Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report.
Ozatli D, Giden AO, Erkurt MA, Korkmaz S, Basci S, Ulas T, Turgut B, Yigenoglu TN, Hacibekiroglu T, Basturk A, Dal MS, Namdaroglu S, Hindilerden F, Hacioglu SK, Cagliyan GA, Ilhan G, Kacmaz M, Uysal A, Merter M, Ekinci O, Dursun FE, Tekinalp A, Demircioglu S, Sincan G, Acik DY, Akdeniz A, Ucar MA, Yeral M, Ciftciler R, Teke HU, Umit EG, Karakus A, Bilen Y, Yokus O, Albayrak M, Demir C, Okan V, Serefhanoglu S, Kartı S, Ozkurt ZN, Eser B, Aydogdu I, Kuku I, Cagirgan S, Sonmez M, Ozet G, Altuntas F. Ozatli D, et al. Transfus Apher Sci. 2023 Apr;62(2):103662. doi: 10.1016/j.transci.2023.103662. Epub 2023 Feb 24. Transfus Apher Sci. 2023. PMID: 36842884 Review.
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS, Ulu BU, Uzay A, Akay OM, Beşışık S, Yenerel MN, Çelik S, Kaynar L, Yücel OK, Deveci B, Sönmez M, Mehtap Ö, Beköz HS, Sunu C, Salim O, Ulaş T, Kartı S, Altuntaş F, Ferhanoğlu B, Tuğlular TF. Dal MS, et al. Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401621 Free PMC article.
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, Tuglular T, Vural F, Yagci M, Alacacioglu I, Aytan P, Goksoy HS, Gulbas Z, Gunes AK, Gurkan E, Hacioglu SK, Karti SS, Kaynar L, Ozdogu H, Paydas S, Solmaz S, Sonmez M, Tekgunduz E, Yildirim R, Ilhan O. Beksac M, et al. Among authors: karti ss. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e474-e484. doi: 10.1016/j.clml.2020.02.017. Epub 2020 Mar 7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482539 Free article. Review.
26 results